Skip to main content

Table 2 Analysis of the factors influencing the postoperative prognosis of patients with giant cell tumor of the extremities

From: The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities

clinical parameters total Number of recurrence Univariate analysis multivariate analysis
HR (95% CI) p-value Adjusted HR (95% CI) p-value
age (year) 38.49 ± 11.10 30 1.00 (0.96~1.03) 0.769 0.99 (0.95~1.03) 0.541
sex
 Male 91 19 1.00   1.00  
 Female 72 11 0.68 (0.32~1.42) 0.302 0.86 (0.39~1.93) 0.717
Companacci stage
 I-II stage 86 6 1.00   1.00  
 III stage 77 24 5.95 (2.42~14.63) < 0.001 3.28 (1.24~8.69) 0.017
surgical method
 expanded curettage 94 17 1.00    
 extensive resection 69 13 1.15 (0.56~2.37) 0.708   
tumor diameter (cm) 5 (4~7) 30 1.12 (0.93~1.36) 0.234   
ALP(U/L) 79 (63~122) 30 1.01 (1.00~1.01) 0.026 1.00 (0.99~1.00) 0.284
white blood cell (109/L) 6.03 (5.12~7.06) 30 1.08 (0.84~1.39) 0.539   
ESR (mm/h) 17 (9~34) 30 1.01 (0.99~1.03) 0.232   
CRP (mg/L) 8.16 (3.77~13.57) 30 1.02 (1.01~1.03) 0.004 1.02 (0.99~1.04) 0.199
NLR
 LNLR 113 10 1.00   1.00  
 HNLR 50 20 5.90 (2.75~12.67) < 0.001 4.18 (1.83~9.57) 0.001
PLR
 LPLR 90 9 1.00   1.00  
 HPLR 73 21 3.17 (1.45~6.92) 0.004 2.15 (0.90~5.14) 0.084
  1. HR, hazard ratio; CI, confidence interval; ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LNLR, low NLR; HNLR, high NLR; LPLR, low PLR; HPLR, high PLR
\